Prostate cancer could soon be treated more effectively thanks to research in York into the disease.
Professor Norman Maitland at the University of York has discovered that a prostate-specific gene is controlled by retinoic acid, a derivative of vitamin A.
The research, which was supported by £2.15 million from Yorkshire Cancer Research a year ago, will make it possible to test whether retinoic acid, given therapeutically, can force prostate cancer stem cells to develop into more specialised cells.
This process, known as differentiation, could kill the stem cells or make them more susceptible to chemotherapy.
This type of therapy has been successful in boosting survival rates among acute promyelomcytic leukaemia patients from 0% to 80%.
A powerful drug proven to stop prostate cancer spreading to other organs could be available by Christmas this year, reports suggest. The Enzalutamide drug, which would be taken once-a-day, has been found to significantly extend the lives of prostate cancer patients by up to 18 months. Drugs company Astellas has submitted an application asking for the permission from the European Medicines Agency (EMA) to bring the drug to market. Read the full story here.
Drinking large amounts of tea could increase the risk of prostate cancer, research has shown. Scientists found that more than seven cups a day raised the chances of men developing the disease by 50%. But whether the link is causal or due to coincidence is still unknown. Read the full story here.
A new prostate cancer treatment could provide more effective treatment with fewer side effects according to a new report. Read the full story here.
According to the latest figures from Cancer Research UK, the number of men with prostate cancer in the UK has risen to 40,000, compared to just 14,000 two decades earlier in 1989. Read the full story here.
Professor Maitland said: "It has been known for many years that low vitamin A in samples of blood is associated with prostate cancer, but nobody knew the mechanisms involved. We have revealed a functional biological link between retinoic receptor expression and our laboratory models of prostate cancers.
"Specifically, the gene we have investigated, the prostate transglutaminase (TGP), is one of the most prostate-specific genes known from the 28,000 in the human genome. We have shown that the TGP gene is controlled by the retinoic acid signalling pathway.
"When retinoic acid gets into a prostate cancer cell, it binds to one of three receptors in the nucleus of the cell. This binding then triggers a sequence of molecular events inside the nucleus which results in the TGP gene being turned on or off.
"We have shown that the same situation also applies to a number of other genes. All of these genes then tell the cell how to behave, to divide for example."
The findings have been published in the scientific journal Nucleic Acids Research.